Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Vétoquinol    VETO   FR0004186856

VÉTOQUINOL

(VETO)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Vetoquinol SA : quaterly sales release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/12/2019 | 09:15am EDT

The company will report its revenue for Q1 2019 on 04/17/2019. Generally, the company reports sales in line with the consensus. In recent months, the 2 analysts from Thomson Reuters consensus have revised their sales estimates upward.

Stocks mentioned in the article
ChangeLast1st jan.
THOMSON REUTERS CORP -0.97% 88.7 Delayed Quote.35.86%
VÉTOQUINOL 0.34% 59 Real-time Quote.16.14%

© MarketScreener.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VÉTOQUINOL
05/31VÉTOQUINOL : Ex-dividend day for final dividend
FA
05/06VETOQUINOL : Programme de rachat - November 2017 (french)
PU
04/29VETOQUINOL : Publishes its registration document and its annual financial report..
PU
04/17Q1 2019 SALES : €90.9 million (up 3.7%)
PU
04/12VETOQUINOL SA : quaterly sales release
03/18VETOQUINOL SA : annual earnings release
2018Q3 2018 SALES : €90.2 million vetoquinol wins second prize for csr in the gaia r..
PU
2018VÉTOQUINOL : 3rd quarter earnings
CO
2018VÉTOQUINOL : Half-year results
CO
2018VÉTOQUINOL : Ex-dividend day for final dividend
FA
More news
Financials (EUR)
Sales 2019 389 M
EBIT 2019 47,5 M
Net income 2019 34,9 M
Finance 2019 49,7 M
Yield 2019 0,80%
P/E ratio 2019 20,0x
P/E ratio 2020 17,3x
EV / Sales2019 1,67x
EV / Sales2020 1,38x
Capitalization 699 M
Chart VÉTOQUINOL
Duration : Period :
Vétoquinol Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VÉTOQUINOL
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 67,67  €
Last Close Price 59,00  €
Spread / Highest target 30,5%
Spread / Average Target 14,7%
Spread / Lowest Target 0,00%
EPS Revisions
Managers
NameTitle
Matthieu Frechin Chief Executive Officer & Non-Independent Director
Étienne Frechin Chairman
Jean-Yves Ravinet Group Chief Operating Officer
Régis Vimal du Monteil Group Director-Finance & Legal Affairs
Jean Deleforge Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
VÉTOQUINOL16.14%769
ZOETIS46.86%59 991
ELANCO ANIMAL HEALTH INC-12.69%10 269
DECHRA PHARMACEUTICALS34.30%3 554
JINYU BIO-TECHNOLOGY CO LTD49.34%2 787
VIRBAC73.99%1 836